SCHEMBL27426145

SCHEMBL27426145

CC(C)(C)OC(=O)NCc1cc(C(=O)OC(C)(C)C)ccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.43
ACACA Q13085 1/20 0.43
KDM4A O75164 2/20 0.42
ATR Q13535 1/20 0.42
NAMPT P43490 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
KDM5B Q9UGL1 3/20 0.41
KDM5C P41229 3/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA9 Q16790 2/20 0.41
KDM4C Q9H3R0 2/20 0.41
KDM5A P29375 1/20 0.41
CA12 O43570 1/20 0.41
BRD4 O60885 1/20 0.41
SREBF2 Q12772 1/20 0.39
CA4 P22748 1/20 0.39
CA7 P43166 1/20 0.39
KDM4E B2RXH2 2/20 0.38
KDM4B O94953 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12682404 0.93 ATR (0.47) ACACBACACAKDM4AATRNAMPT
SCHEMBL31133034 0.93 ATR (0.47) ACACBACACAKDM4AATRNAMPT
SCHEMBL509487 0.90 KDM5B (0.53) ACACBACACANAMPTKDM5BKDM5C
SCHEMBL30097021 0.89 ACACB (0.46) ACACBACACAKDM4AATRNAMPT
SCHEMBL508770 0.89 ACACB (0.46) ACACBACACAKDM4AATRNAMPT
SCHEMBL10285171 0.88 KDM5A (0.46) ACACBACACAKDM4AATRNAMPT
SCHEMBL21455931 0.85 L3MBTL1 (0.45) ACACBACACAKDM4AATRNAMPT
SCHEMBL2388031 0.84 KDM5B (0.48) KDM4AKDM5BKDM5CKDM4CKDM5A
SCHEMBL16020311 0.83 KDM4A (0.44) ACACBACACAKDM4AATRNAMPT
SCHEMBL23706062 0.83 ACACB (0.48) ACACBACACAKDM4ANAMPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216513-A1 FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE NOVARTIS AG (CH) 2024-07-04 US disclosed
US-20240216513-A1 FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE NOVARTIS AG (CH) 2024-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240216513-A1 FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE FASN, FABP1, SCD ACACB 104/4885ACACA 166/4885KDM4A 2365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.